- ISIS has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $34.0 million.
- ISIS has traded 163,676 shares today.
- ISIS is up 3.4% today.
- ISIS was down 5.3% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in ISIS with the Ticky from Trade-Ideas. See the FREE profile for ISIS NOW at Trade-Ideas More details on ISIS: Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. Currently there are 3 analysts that rate Isis Pharmaceuticals a buy, 2 analysts rate it a sell, and 2 rate it a hold. The average volume for Isis Pharmaceuticals has been 1.4 million shares per day over the past 30 days. Isis has a market cap of $3.7 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.78 and a short float of 13.1% with 10.42 days to cover. Shares are up 191.6% year to date as of the close of trading on Monday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Isis Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Highlights from the ratings report include:
- ISIS's very impressive revenue growth greatly exceeded the industry average of 10.4%. Since the same quarter one year prior, revenues leaped by 103.3%. Growth in the company's revenue appears to have helped boost the earnings per share.
- Powered by its strong earnings growth of 43.24% and other important driving factors, this stock has surged by 293.76% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the stock's future course, our hold rating indicates that we do not recommend additional investment in this stock despite its gains in the past year.
- ISIS PHARMACEUTICALS INC has improved earnings per share by 43.2% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past year. We feel that this trend should continue. This trend suggests that the performance of the business is improving. During the past fiscal year, ISIS PHARMACEUTICALS INC continued to lose money by earning -$0.65 versus -$0.85 in the prior year. This year, the market expects an improvement in earnings (-$0.52 versus -$0.65).
- The net income growth from the same quarter one year ago has exceeded that of the S&P 500 and greatly outperformed compared to the Biotechnology industry average. The net income increased by 34.7% when compared to the same quarter one year prior, rising from -$37.64 million to -$24.57 million.
- The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, ISIS PHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and the S&P 500.
- You can view the full Isis Pharmaceuticals Ratings Report.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.